ADMINISTRATION OF LEVODOPA IN A PARKINSON’S PATIENT USING A NOVEL ORAL AND MAXILLOFACIAL ROUTE – A FIRST IN HUMAN STUDY - Thirunavukarasu, Suresh; Ramanan, Balasubramanian Bala Venkata; Suresh, Sathya Krishnan; Antonisamy, Vincent Jayakumar; Varadharaj, Devi; Shanmugam, Paranjothi; Verma, Kavita; Elumalai, Canmany; Selvakumar, Gladson; Elumalai, Ahila; Prabahar, Lydia; Janardhanan, Hridwik Adiyeri; et al. (medRxiv, 2023)
Parkinson’s disease is characterized by loss of nigrostriatal dopaminergic neurons in the brain. Dopamine cannot be administered systemically as a treatment because dopamine does not cross the blood-brain-barrier. Oral levodopa is the gold standard till date. Currently, in patients who show poor response to oral levodopa, the drug can be delivered through alternate routes like inhalation and continuously by intestinal and subcutaneous routes. In this report, a novel oral and maxillofacial route was used for the first time in the world to administer levodopa in a Parkinson’s patient and its efficacy was compared with the oral route of administration.Competing Interest StatementThe authors, Anoop U.R and Kavita Verma are stated as the inventors of the drug delivery system and the method of drug delivery and as applicants in the granted patents AU2016300184; US11,207,461B2, IN413914; IN360982 and in the patent application PCT/IB2016/053899 with National Phase Entry into India, European Patent Office and Canada.Clinical TrialCTRI/2023/04/051539Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of INDIRA GANDHI GOVERNMENT GENERAL HOSPITAL AND POST GRADUATE INSTITUTE, PUDUCHERRY gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes